Comparing antibody and small-molecule therapies for cancer. - Wikidata - awgldk - TriplyDB

Comparing antibody and small-molecule therapies for cancer.

Comparing antibody and small-molecule therapies for cancer.

http://www.wikidata.org/entity/Q34560075

about

Vascular endothelial growth factor inhibitors: investigational therapies for the treatment of psoriasis Quercetin-induced ubiquitination and down-regulation of Her-2/neu Genetic targeting of the kinase activity of the Met receptor in cancer cells Genomic characterization of esophageal squamous cell carcinoma: Insights from next-generation sequencing Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC).Antibody-drug conjugates as novel anti-cancer chemotherapeutics Specificity delivers: therapeutic role of tumor antigen-specific antibodies in pancreatic cancer Chemokine receptor-specific antibodies in cancer immunotherapy: achievements and challenges Toward a magic or imaginary bullet? Ligands for drug targeting to cancer cells: principles, hopes, and challenges Novel immunotherapeutic strategies of gastric cancer treatment ISO-66, a novel inhibitor of macrophage migration, shows efficacy in melanoma and colon cancer models Nonsmall cell lung cancer therapy: insight into multitargeted small-molecule growth factor receptor inhibitors Breast cancer chemoprevention: old and new approaches PET Metabolic Biomarkers for Cancer Mechanisms of action of therapeutic antibodies for cancer Nanovehicles as a novel target strategy for hyperthermic intraperitoneal chemotherapy: a multidisciplinary study of peritoneal carcinomatosis Lysosomotropic properties of weakly basic anticancer agents promote cancer cell selectivity in vitro Interferon-α/β and anti-fibroblast growth factor receptor 1 monoclonal antibody suppress hepatic cancer cells in vitro and in vivo Vicrostatin - an anti-invasive multi-integrin targeting chimeric disintegrin with tumor anti-angiogenic and pro-apoptotic activities Lenvatinib therapy for the treatment of patients with advanced renal cell carcinoma.Platelet-derived growth factor receptor/platelet-derived growth factor (PDGFR/PDGF) system is a prognostic and treatment response biomarker with multifarious therapeutic targets in cancers.Beyond new chemical entities: advancing drug development based on functional versatility of antibodies Differential screening of phage-ab libraries by oligonucleotide microarray technology.E-clonal antibodies: selection of full-length IgG antibodies using bacterial periplasmic display.A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma.Bayesian clustering and feature selection for cancer tissue samples Rapid detection and profiling of cancer cells in fine-needle aspirates.Selection of full-length IgGs by tandem display on filamentous phage particles and Escherichia coli fluorescence-activated cell sorting screening.Photo-inducible crosslinked nanoassemblies for pH-controlled drug release BMP9 inhibits proliferation and metastasis of HER2-positive SK-BR-3 breast cancer cells through ERK1/2 and PI3K/AKT pathways.Biologic effects of platelet-derived growth factor receptor α blockade in uterine cancer.Dual inhibition of EGFR at protein and activity level via combinatorial blocking of PI4KIIα as anti-tumor strategy.Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer.Targeted Therapy Database (TTD): a model to match patient's molecular profile with current knowledge on cancer biology Antibody targeting intracellular oncogenic Ras mutants exerts anti-tumour effects after systemic administration.The role of lysosomes in limiting drug toxicity in mice.Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy Endothelial-Monocyte Activating Polypeptide II Suppresses the In Vitro Glioblastoma-Induced Angiogenesis by Inducing Autophagy.Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases?Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma

P2860

Q22305863-70758850-C2F7-4FC0-9C78-D17AB65D3922 Q24646978-C2323CF4-E9B9-4E96-A32F-FBDBB1BAC5AF Q24675200-3D8900F4-B25F-465E-8A38-1F97F01E88EA Q26768533-4AF9B9F1-9EC7-4DC8-9827-76849D88E769 Q26775394-19D35EF3-B450-4876-B941-B3769459987A Q26800175-D5CDF6F5-4626-4D7E-8114-E6AE7E104AFC Q26853171-92B889A8-8767-40B4-AE45-B8B8749CF317 Q26866236-9BA942B1-4B91-4B46-95BC-A11A11A533DE Q26995399-A2C95EC1-8DD6-4176-A7DB-1FC2251F0227 Q27011232-8245DEE2-3FD4-4C29-873D-C47E4FEB03D2 Q27684783-FE35EDDD-D2A2-4EA6-A4E5-16A88C4E3F50 Q27693185-E6720DDE-90C1-41DF-AD2E-E602F93C3630 Q27693259-3EEBE99F-4B6F-43A6-BCEA-36E426169A49 Q28074449-658CADAA-13A8-4411-83F3-977ED9CE28DB Q28385366-9C8194B8-800A-4319-A7D6-8D5B76012FD1 Q28395895-4FD49358-E8A5-45E4-A06B-F4F4E17CDBFD Q28484924-6847D618-3ABD-41ED-BC0D-0E464300955A Q28740388-B0976736-1ABB-47FC-878D-3D28B8F29F58 Q28751757-4673FB66-0D2A-4CD4-B9B8-1A4D4B87C46B Q30249385-B4123428-21ED-4F9B-BF6B-B48AFC46F74C Q30250273-13A5733F-7983-4FB1-A754-621D423F0C42 Q30386064-1BF25340-CC9F-45BA-AA98-6F4F0AB97EC6 Q33317276-77F32242-87A9-4E9F-8D95-E41144F9064B Q33379067-E5877572-414D-4F3B-ADBB-B6413D3D12F2 Q33411061-79C4113F-1E52-4E63-AC2F-642AEF859870 Q33419521-FB53592F-EACB-4470-BA39-3C25A123D88E Q33484683-4E306926-7818-4932-81DB-89E60FC8AF99 Q33566182-CEA0B64E-3B21-4FF7-AE06-7FA3F46B9041 Q33573812-153A9DD5-1BD2-4017-AAEB-46A3A331A8F5 Q33578209-9EB48011-496E-462D-8BE0-E647E29AAAC0 Q33625089-E6C06594-DBAF-4DBB-860F-E64A08C7A8BC Q33632845-E854B8A3-F8C7-4BEB-9B82-01E3424953F6 Q33645821-E8F9C152-EBEF-4F65-8151-F938A4042687 Q33656600-626E1193-E3A1-4A38-90C8-A9EB65988C13 Q33701979-52F739A3-A144-411A-A8B9-BBA56763B267 Q33755217-5B3B8AFE-B077-4C2A-A76B-AB0523F148C1 Q33828409-16924C30-B4CA-47D7-9060-EF2802970373 Q33847497-A249DEBA-E036-4BF2-AA94-0C987EC3346C Q33890792-FEBE971B-ADFF-4590-9CAF-1F23C3F445A9 Q33918113-33B93BC7-8929-47E7-9FEF-7A7958BD7A92

P2860

Comparing antibody and small-molecule therapies for cancer.

http://www.wikidata.org/entity/Q34560075

description

2006 nî lūn-bûn

@nan

2006 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Comparing antibody and small-molecule therapies for cancer.

@ast

Comparing antibody and small-molecule therapies for cancer.

@en

Comparing antibody and small-molecule therapies for cancer.

@nl

type

label

Comparing antibody and small-molecule therapies for cancer.

@ast

Comparing antibody and small-molecule therapies for cancer.

@en

Comparing antibody and small-molecule therapies for cancer.

@nl

prefLabel

Comparing antibody and small-molecule therapies for cancer.

@ast

Comparing antibody and small-molecule therapies for cancer.

@en

Comparing antibody and small-molecule therapies for cancer.

@nl

P1433

Q34560075-5A34D63F-1B2A-49B9-B0AE-F15DF1364404

P1476

Q34560075-3F52E37B-794B-452B-8AEB-4AA3702E1821

P2093

Q34560075-4DFEC784-6845-4E9D-8346-D5DC4173BB4F

Q34560075-C163E6D7-5034-4AD0-8C86-D411DF0FBF1D

P2888

Q34560075-DA6955EE-B6E6-4BBB-BEE5-B763D8345DEA

P304

Q34560075-43883380-4E33-462F-BC90-DE748207558F

P31

Q34560075-FBC13F5D-99B8-4A69-9E21-AF19E4F2FE02

P356

Q34560075-5973F0D3-BF3C-4699-88E7-009183698DA7

P407

Q34560075-12BA5886-E536-401A-A62D-2F276ED008F3

P433

Q34560075-75CB8837-7708-422A-83B9-465B6DC7E6E0

P478

Q34560075-8900A839-8664-40A3-B4C6-4EA4F1A01BAA

P577

Q34560075-52396D05-C290-4B04-8456-1F7A9DC4452C

P5875

Q34560075-C512F883-A7EC-437C-BDB3-F0AB350FC9F3

P6179

Q34560075-DB160D96-330E-4E57-BFC5-B52B4B07E14E

P698

Q34560075-187488A0-84F7-4BD7-8FC9-4C0A0A4F02BB

P921

Q34560075-BE1BD5E5-6C98-4E7B-BCC1-DA688E2C373C

P356

P1433

Nature Reviews Cancer

P1476

Comparing antibody and small-molecule therapies for cancer.

@en

P2093

Akinori Takaoka

http://www.w3.org/2001/XMLSchema#string

Kohzoh Imai

http://www.w3.org/2001/XMLSchema#string

P2888

P304

714-727

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NRC1913

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2006-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6859631

http://www.w3.org/2001/XMLSchema#string

P6179

1020265732

http://www.w3.org/2001/XMLSchema#string

P698

16929325

http://www.w3.org/2001/XMLSchema#string

P921